Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported Research And Development Expense of $300.27 million for the year ending 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +8.7% in Research And Development Expense from 2024 to 2025.
- This data is from IOVANCE BIOTHERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $300.27 million | Fiscal year 2024: $276.23 million | Fiscal year 2023: $333.19 million | Fiscal year 2022: $294.78 million | Fiscal year 2021: $259.04 million | Fiscal year 2020: $201.73 million | Fiscal year 2019: $166.02 million | Fiscal year 2018: $99.83 million | Fiscal year 2017: $71.62 million | Fiscal year 2016: $26.94 million | Fiscal year 2015: $15.47 million | Fiscal year 2014: $3.85 million | Fiscal year 2013: $2.15 million | Fiscal year 2012: $1.66 million | Fiscal year 2011: $1.76 million | Fiscal year 2010: $171.5 thousand | Fiscal year 2009: $0.00.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: